Brokerage Firm Rating Update on Zoetis (ZTS)

Zoetis (ZTS) : 6 brokerage houses believe that Zoetis (ZTS) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Zoetis (ZTS). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 9 Wall Street Analysts endorse the stock as a Buy with a rating of 1.67.

Zoetis (ZTS) : The highest level Zoetis (ZTS) is projected to reach is $62 for the short term and the lowest estimate is at $49. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $54.43 and the possibility the share price can swing is $5.5.


For the current week, the company shares have a recommendation consensus of Buy. Also, Barclays maintains its rating on Zoetis (NYSE:ZTS). The global brokerage major raises the current price target from $45 per share to $49 per share. Analysts at the Barclays have a current rating of Equal-weight on the shares. The rating by the firm was issued on August 4, 2016.

Zoetis (NYSE:ZTS): The stock opened at $51.44 and touched an intraday high of $52.05 on Wednesday. During the day, the stock corrected to an intraday low of $51.3901, however, the bulls stepped in and pushed the price higher to close in the green at $52.04 with a gain of 1.46% for the day. The total traded volume for the day was 3,766,819. The stock had closed at $51.29 in the previous trading session.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *